ReviewChinese medical journal2022
Non-invasive tests of non-alcoholic fatty liver disease.
Review in Chinese medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Nonlinear Associations of Estimated Pulse Wave Velocity With Hepatic Steatosis and Liver Stiffness in Community-Based People.Gastroenterology research · 2026Article
- Evolving B-mode ultrasound-based techniques for assessing metabolic dysfunction-associated steatotic liver disease: Now and beyond.Liver research (Beijing, China) · 2026Review
- Harmonic analysis of radial pulse in traditional Chinese medicine: physiological alterations associated with hepatitis B and hepatitis C infections.Frontiers in medicine · 2026Article
- Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Positive Association of the Dietary n-6/n-3 PUFA Ratio with Fatty Liver in Mexican Adults.Healthcare (Basel, Switzerland) · 2025Article
- Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease.Gut and liver · 2025Article
- The prognostic value of the triglyceride-glucose index in predicting recurrence of acute pancreatitis: a retrospective cohort study.Nutrition & metabolism · 2025Article
- Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.Diabetes, obesity & metabolism · 2025Review
- Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia.Journal of diabetes research · 2025Article
- Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.Clinical epidemiology · 2025Review
- Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024).Journal of clinical and translational hepatology · 2024Article
- Response to "Letter to Editor From Ishaq MU et al: 'Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease'".Journal of the Endocrine Society · 2024Article
- Noninvasive models for the prediction of liver fibrosis in patients with chronic hepatitis B.BMC gastroenterology · 2024Article
- [Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression.Clinical and molecular hepatology · 2024Article
- Synthesis and preclinical evaluation of aScientific reports · 2024Article
- Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis.Journal of health economics and outcomes research · 2024Article
- Article
- Review and expert opinion on MAFLD, oxidative stress and multifunctional management.Drugs in context · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractFor the detection of steatosis, quantitative ultrasound imaging techniques have achieved great progress in past years. Magnetic resonance imaging proton density fat fraction is currently the most accurate test to detect hepatic steatosis. Some blood biomarkers correlate with non-alcoholic steatohepatitis, but the accuracy is modest. Regarding liver fibrosis, liver stiffness measurement by transient elastography (TE) has high accuracy and is widely used across the world. Magnetic resonance elastography is marginally better than TE but is limited by its cost and availability. Several blood biomarkers of fibrosis have been used in clinical trials and hold promise for selecting patients for treatment and monitoring treatment response. This article reviews new developments in the non-invasive assessment of non-alcoholic fatty liver disease (NAFLD). Accumulating evidence suggests that various non-invasive tests can be used to diagnose NAFLD, assess its severity, and predict the prognosis. Further studies are needed to determine the role of the tests as monitoring tools. We cannot overemphasize the importance of context in selecting appropriate tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.